Buffalo

Chicagoland Area

Cincinnati

Dayton

Columbus

Columbus South

Cleveland

• For patients with insurance:
  Most insurance plans cover COVID-19 testing under the CARES Act. Please contact your insurance carrier for full details on your coverage, as individual plans can vary. Base visit, co-pays, and other necessary service charges may apply.
• For patients without insurance:
  COVID-19 PCR testing for patients without insurance is $100 in addition to the base visit charge of $130. Any other medical services received, such as X-rays or diagnostic testing, will result in additional charges. Testing for travel and events only: COVID-19 PCR testing for the purpose of travel or events is $100 in addition to the base visit charge of $50. Payment is due at the time of service. If you’d prefer to pay in installments, we offer an interest-free “buy now, pay later” option that allows patients to pay their bill over time in four installments.

Tests administered at WellNow centers, by the times below, will return results within 24 hours. All other PCR results will be returned within 48 hours.

For the most updated info on PCR results, visit our patient portal directly. 

Please note that all positive COVID-19 PCR swab test results will receive a direct phone call from one of our team members.

You will receive a text notification confirming we received and are processing your sample, as well as a second text notification when your results are ready. Please login to the Patient Portal to ensure you can access when your results are ready. Login instructions can be found here.

All positive COVID-19 PCR swab test results will receive a direct phone call from one of our team members.

In October, 2020, the antiviral drug Veklury (also known as Remdesivir) was approved by the FDA for use in hospitals for the treatment of certain COVID-19 patients requiring hospitalization. Veklury is administered as an I.V. and is not available in urgent care settings.

Antiviral oral pills, Molnupiravir (developed by Merck/Ridgeback Biotherapeutics) and Ritonavir (developed by Pfizer), have both been submitted to the FDA for emergency use authorization. If approved, the antiviral pills could be available by prescription only, for certain high-risk patients who receive a positive COVID-19 result, by the end of 2021.

Antiviral drugs are taken by mouth for five days starting soon after a patient with mild-to-moderate COVID-19 and at least one risk factor for developing severe illness tests positive for the virus.

At this time, antiviral treatments administered through an I.V. (such as Veklury, also known as Remdesivir) are only available in hospital settings for certain COVID-19 patients requiring hospitalization.

Antiviral oral pills, Molnupiravir (developed by Merck/Ridgeback Biotherapeutics) and Ritonavir (developed by Pfizer), have both been submitted to the FDA for emergency use authorization.

If approved, the pills will be available by prescription only for adult patients with mild-to-moderate COVID-19 who receive a positive SARS-CoV-2 diagnostic test result and who have at least one risk factor for developing severe illness.

Antiviral treatments administered through an I.V. (such as Veklury, also known as Remdesivir) are currently only available in hospital settings for certain COVID-19 patients requiring hospitalization.

The FDA is currently evaluating antiviral oral pills Molnupiravir (developed by Merck/Ridgeback Biotherapeutics) and Ritonavir (developed by Pfizer) for emergency use authorization. If approved, the pills will be available by prescription only for certain high-risk adult patients who receive a positive COVID-19 result.

Antiviral drugs are taken by mouth for 5 days starting soon after a patient with mild-to-moderate COVID-19 and at least one risk factor for developing severe illness tests positive for the virus.